Louis Edward Tamayo Sells 4,641 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.49, for a total value of $20,838.09. Following the completion of the transaction, the chief financial officer owned 97,024 shares in the company, valued at $435,637.76. The trade was a 4.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Stock Down 4.5%

LXEO stock traded down $0.21 during mid-day trading on Wednesday, hitting $4.45. The company had a trading volume of 852,557 shares, compared to its average volume of 948,339. The company has a 50-day moving average price of $5.16 and a 200 day moving average price of $6.67. Lexeo Therapeutics, Inc. has a 12-month low of $3.60 and a 12-month high of $10.99. The company has a market capitalization of $349.41 million, a price-to-earnings ratio of -3.07 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, analysts expect that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on LXEO shares. Weiss Ratings downgraded shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of large investors have recently added to or reduced their stakes in LXEO. Allworth Financial LP boosted its holdings in shares of Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Lexeo Therapeutics by 69.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Lexeo Therapeutics during the fourth quarter valued at approximately $37,000. California State Teachers Retirement System boosted its stake in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in Lexeo Therapeutics in the second quarter valued at approximately $50,000. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.